Investors searching for ASX growth shares often look for the same ingredients: market leadership, a strong competitive moat, and a share price that doesn’t fully reflect future potential.

Telix Pharmaceuticals Ltd (ASX: TLX) and Catapult Sports Ltd (ASX: CAT) fit that description.

Both companies have faced significant share price pressure over the past year. Telix shares are up 26% year to date but remain down 43% over 12 months. Catapult has fared even worse, falling 28% in 2026 and 47% over the past year.

Despite those declines, analysts see substantial upside ahead for the ASX shares. Here’s why.

Telix Pharmaceuticals

Telix develops radiopharmaceutical products used to diagnose and treat cancer. Its flagship products target some of the largest oncology markets globally, giving the company exposure to a rapidly growing area of healthcare.

One of Telix’s biggest strengths is its moat. Developing radiopharmaceuticals requires specialised expertise, manufacturing capabilities, regulatory approvals, and distribution networks that are difficult and expensive to replicate. Those barriers help protect established players such as Telix.

After a difficult period, the ASX growth share appears to have found its groove since February. The rebound began when the company confirmed it had filed for a key regulatory approval in Europe.

Momentum continued into April. Telix announced that the US Food and Drug Administration had accepted its New Drug Application for TLX101-Px (Pixclara®), an important milestone for the business. It also revealed a major collaboration with US biotechnology giant Regeneron Pharmaceuticals, further strengthening confidence in its long-term prospects.

Analysts remain highly optimistic. TradingView data shows the majority of brokers rate the $5 billion ASX growth share as a strong buy. The most bullish price target sits at $31.64 per share, implying upside of approximately 123% from current levels.

Morgans is also positive on the stock, with a $24.33 price target, which suggests a 71% upside. The broker recently noted that increasing consolidation across the healthcare sector could generate additional interest in Telix shares.

Catapult Sports

Catapult develops athlete performance and analytics technology used by professional sporting teams around the world.

Its solutions help coaches and performance staff monitor player workloads, reduce injury risks, analyse performance, and improve decision-making. The technology is widely used across major sporting organisations, including teams in the AFL, NRL, Premier League, NFL, NBA, MLB, and international rugby competitions.

That extensive customer base gives Catapult a significant competitive advantage. Once teams integrate the company’s hardware, software, and performance data into their operations, switching providers becomes difficult. This creates sticky customer relationships and recurring revenue streams.

Despite these strengths, investors have remained cautious, helping drive the share price of the ASX growth share sharply lower over the past year.

Analysts, however, remain overwhelmingly bullish. TradingView data shows every analyst covering Catapult currently rates it as either a buy or strong buy. The average price target stands at $5.72, implying upside of approximately 94% from current levels. The most optimistic forecast suggests the ASX growth stock could rise by as much as 175% over the next year.

Morgans has a buy rating and a $5.40 target price. Based on the current share price of $2.95, that points to potential gains of roughly 83%.

The post 2 ASX growth shares that could double your money appeared first on The Motley Fool Australia.

More reading

• Here are the 10 most shorted ASX shares
• Healthcare shares led the ASX 200 last week. Is a sector comeback underway?
• Why these 2 battered ASX tech shares look ready to surge
• 3 top ASX 300 shares tipped to jump 30% to 50%
• 3 incredible ASX growth shares tipped to rise 20% to 70%

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Catapult Sports and Telix Pharmaceuticals. The Motley Fool Australia has positions in and has recommended Catapult Sports. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Commonwealth Bank of Australia (ASX: CBA) shares have pulled back from their highs, but they still trade at a sizeable premium to the other major banks.

At around $163.56 at the time of writing, CBA shares are above their 52-week low of $146.97 but still well below their 52-week high of $192.

That creates an interesting setup. The banking sector is dealing with a difficult backdrop, including higher interest rates and proposed changes to negative gearing weighing on the housing market. But I think there are still good reasons to buy CBA shares today.

Quality counts in a tougher banking market

The first reason is quality. When conditions become more uncertain, I think investors have a strong reason to focus on the highest-quality bank in the sector. CBA has long held a powerful position in Australian banking, helped by its huge customer base, strong deposit franchise, digital strength, and trusted brand.

Those advantages can be especially useful when the operating environment is harder.

Higher interest rates can put pressure on borrowers. Housing market sentiment can shift. Competition for deposits and mortgages can affect margins. Credit quality also needs watching when households and businesses are under pressure.

In that environment, I think CBA’s scale and customer relationships matter.

The bank has a broad presence across home lending, deposits, business banking, payments, cards, apps, and everyday financial services. It is deeply embedded in the financial lives of many Australians, and that gives it a level of resilience that is hard to replicate.

CBA shares are rarely cheap. But I think the premium reflects a business that investors trust to navigate more difficult periods better than most.

The dividend still has appeal

The second reason is income. CBA shares may not offer the highest dividend yield among the major banks, but the dividend still looks attractive, particularly because it is expected to be fully franked.

According to CommSec, consensus estimates point to dividends per share of $5.10 in FY26 and $5.15 in FY27.

Based on the current share price of around $163.56, that implies forward dividend yields of approximately 3.1% in both years.

For investors who can use franking credits, the grossed-up income picture could look more appealing.

I also think investors should consider the total return potential. A bank share does not need to have the highest yield on the ASX to be worthwhile. If CBA can keep paying reliable dividends while also delivering capital growth over time, the overall return can still be attractive.

That combination is why I think CBA remains such a popular long-term holding.

Earnings support the premium

The third reason is the earnings base. CommSec consensus estimates suggest CBA could generate earnings per share of $6.54 in FY26 and $6.72 in FY27.

At the current share price, that puts the bank on a price-to-earnings (P/E) ratio of about 25 times FY26 earnings and 24 times FY27 earnings.

That is a premium multiple for a bank. But CBA is also the bank with the strongest market reputation, and I think investors have historically been willing to pay more for its quality, consistency, and digital leadership.

The key question is whether CBA can keep justifying that premium.

I think it can. The bank’s technology investment, customer engagement, balance sheet strength, and ability to generate substantial profits all support the case. It may not deliver explosive growth, but it does not need to. A high-quality bank with strong dividends, disciplined lending, and a trusted position in the economy can still create value for shareholders over time.

Foolish Takeaway

CBA shares are not priced like a bargain-bank stock, and that is unlikely to surprise anyone who follows the sector.

But I do not think the investment case rests on the bank suddenly becoming cheap. It rests on the strength of the franchise, the role CBA plays in Australian financial life, and the likelihood that patient investors can still be rewarded through a mix of earnings, dividends, and time.

The sector faces uncertainty, especially around borrowers, housing sentiment, and competition. Even so, for long-term investors looking for exposure to Australian banking, I think CBA remains a share worth considering.

The post 3 big reasons to buy CBA shares appeared first on The Motley Fool Australia.

More reading

• 3 ASX dividend shares with bigger yields than CBA
• Here’s where I would invest $5,000 in ASX shares
• 4 ASX ETFs to help you sleep through market crashes
• Invested in ASX 200 bank shares for dividends? This fundie prefers other stocks
• 5 ASX 200 shares I would buy if I were starting from scratch

Motley Fool contributor Grace Alvino has positions in Commonwealth Bank Of Australia. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) shares have taken a severe hit over the past year. The stock is down around 34% year to date and roughly 52% over the past 12 months at the time of writing.

That kind of drawdown has forced investors to rethink the once-premium growth story, and analyst sentiment has clearly turned more cautious. Let’s break down why.

Three major pillars

CSL is one of the world’s leading biotechnology companies, built on three major pillars. It collects and processes blood plasma through CSL Behring, supplies influenza vaccines through CSL Seqirus, and operates CSL Vifor, which focuses on iron deficiency and nephrology treatments after its major acquisition of Vifor Pharma.

For years, CSL shares were treated as a defensive growth compounder with strong pricing power and resilient demand. That reputation is now being tested as growth slows and integration challenges emerge.

Why CSL shares are under pressure

The sell-off has not come from a single issue. It has built gradually as investors reassess earnings quality, acquisition outcomes, and valuation support.

One of the clearest warning signs has been the downgrade cycle building across FY26 expectations and beyond. Analysts have trimmed revenue and earnings forecasts as they factor in weaker contributions from CSL Vifor and slower growth across parts of the business.

On top of that, CSL has recognised around $5 billion in impairments linked to acquired assets. While these are non-cash charges, they signal that earlier assumptions about the value and performance of those assets may have been too optimistic.

CSL Vifor is proving harder to fix than expected

The real battleground for sentiment is CSL Vifor. The business was supposed to be a strategic growth engine, particularly in nephrology, but it continues to underperform.

Ord Minnett has taken a notably bearish view on CSL shares, arguing the market is still underestimating the scale of the Vifor challenge. The broker explains:

Ord Minnett has reviewed its CSL (CSL) model further with a focus on its Vifor nephrology business that is facing challenges which, in our view, are being underestimated by the broader market. Our estimates for Vifor revenue and operating profit in FY27 are below consensus estimates by 15% and 32%, respectively, while our forecasts for operating profit across the FY27–FY29 horizon are more than 10% below market expectations.

That gap between broker expectations and consensus highlights a simple risk: earnings may still be drifting lower.

Higher interest rates are compressing valuation

The final pressure point is macro-driven. Higher interest rates have hit growth stocks hard, and CSL shares are no exception.

When interest rates rise, future earnings are discounted more heavily. That matters for CSL because a large part of its valuation depends on long-term growth assumptions rather than near-term earnings. As discount rates increase, that long-term value becomes less attractive in present terms.

What next for CSL shares?

CSL is still a global leader in plasma therapies and vaccines, and its core businesses remain highly valuable. However, the market is no longer willing to pay a premium multiple without clearer proof that growth is re-accelerating. That’s why analysts at Peak Asset Management have a sell rating on CSL shares.

Until CSL Vifor stabilises and earnings forecasts stop drifting lower, sentiment is likely to remain cautious. For now, the stock is still working through a reset in expectations, and that process rarely happens quickly.

The post 3 reasons why experts think CSL shares are a sell appeared first on The Motley Fool Australia.

More reading

• 3 ASX healthcare shares to sell despite signs of sector rebound
• Buy, hold, sell: Life360, Woodside, CSL shares
• Why CSL, Westpac, and this big-name ASX 200 share could be sells
• Here’s where I would invest $5,000 in ASX shares
• Buy, hold, sell: CSL, Steadfast, and Wesfarmers shares

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.